BB BIOTECH AG: Challenging first quarter for biotech investments
(Thomson Reuters ONE) -
BB BIOTECH AG /
BB BIOTECH AG: Challenging first quarter for biotech investments
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Interim Report of BB Biotech AG as of March 31, 2016
Major regulatory approvals and significant clinical read-outs for portfolio
companies pending
After a long and steady advance, the biotech sector experienced a steep
correction of nearly 23% in the first quarter of 2016 (NBI in USD). Profit-
taking and the debate among US presidential candidates over drug prices were the
primary triggers for this short-term downturn. BB Biotech shares also retreated,
by 16.5% in CHF, 17.4% in EUR and 13.0% in USD (incl. the dividend pay-out),
which was far less than the benchmark index. The shares' discount to Net Asset
Value therefore virtually vanished. BB Biotech reports a net loss of CHF 1.2 bn
for the first quarter of 2016 compared to a net profit of CHF 379 mn for the
same period last year. Although biotech stocks did not gain on news reports of
product approvals and successful clinical outcomes in the first quarter, the
outlook remains positive. BB Biotech views the current correction as a temporary
move and is maintaining its positioning. At the Annual General Meeting on March
17, 2016, the Board of Directors reiterated its intention to pay out a dividend
equivalent to a 5% yield.
2016 started off with a significant equity market correction. With equity
indices stabilizing and recovering some of the substantial losses, the first
quarter total return for the S&P 500 index was flat in USD, down 7.2% in EUR for
the DAX and down 10.2% in CHF for the SMI.
Following several years of significant outperformance against the broad equity
indices, the biotech sector valuations fell in association with profit-taking
fueled by US presidential election campaigns promising hardly realizable moves
on drug pricing. The NBI fell 22.9% in USD in Q1 2016, one of the most
significant quarterly declines in history of the biotech equity markets.
BB Biotech's performance for the first quarter of 2016
BB Biotech weathered this storm by focusing on high quality investments and a
long term view. The total return for BB Biotech's share was better than the
sector indices by around 10% and also ahead of the portfolio. Nevertheless, BB
Biotech's shares declined 16.5% in CHF, 17.4% in EUR and 13.0% in USD, including
the dividend payment. The difference between share price and the Net Asset Value
- which was 18% at the end of 2015 - reduced to almost zero with the share price
trading close to the book value of the assets.
The portfolio showed an overall loss of 30.1% in CHF, 30.5% in EUR and 27.1% in
USD. Proportionally greater exposure to smaller and mid cap holdings, with the
leverage maintained throughout the market correction, and the depreciation of
the US dollar to the Euro and the Swiss Franc all resulted in a significant
temporary drop in the value of the net assets of BB Biotech. For Q1 2016, BB
Biotech's net loss amounts to CHF 1.2 bn, compared to a net profit of CHF 379 mn
for the same period in 2015.
Total return calculations include the dividend distribution of CHF 14.50 per
share in accordance with BB Biotech's proposed dividend policy and as approved
by shareholders at this year's AGM on March 17, 2016. The distribution is
another substantive increase compared to the dividend of last year, driven by
the share price appreciation of 2015.
Continued distribution and a five-for-one share split
BB Biotech paid its proposed dividend of CHF 14.50 per share, expending the
remaining paid-in capital reserves by distributing CHF 12.25 per share, plus a
regular cash dividend of CHF 2.25 per share. The board announced it will
continue the current distribution policy in the future, paying a regular
dividend calculated at 5% of the average December share price.
The share repurchase program ongoing throughout 2015 and the first quarter of
2016 reached was closed prior to the AGM having acquired 770 000 shares (before
split) of BB Biotech through the second trading line. The AGM approved the
cancellation of these shares. Additionally, BB Biotech implemented a five-for-
one share split on March 29, 2016. The total number of shares outstanding post
the split is 59 250 000, or 55 400 000 after the deletion of the shares
repurchased through thesecond trading line which is planned earliest in the
second quarter of 2016.
A new share-repurchase program of a maximum of 10% of the outstanding shares, or
5 540 000 shares, was approved at the AGM and is required to close within a 36-
months window. In combination with the dividend pay-out, this enables the
continuation of the structured distribution policy to return capital to
shareholders, providing them with up to 10% annual return.
First quarter portfolio activity
Despite economic challenges and substantially increased volatility in the
biotech equity markets, BB Biotech maintained most of its portfolio positions.
The holdings in Swedish Orphan Biovitrum and Actelion were marginally reduced.
In contrast, taking advantage of lower share prices, BB Biotech increased
holdings in selected US smaller and mid cap companies such as Ionis, Incyte,
Radius, Halozyme, Alnylam, Cempra, Sage, Esperion and Prothena. The team also
increased the holding in Cidara, initiated in the fourth quarter 2015,
throughout the first quarter 2016 and sold all of the remaining shares in the
Tetraphase position following their failed Phase III study for Eravacyline.
At the beginning of 2016, BB Biotech's investment leverage was CHF 140.5 mn, or
3.5% of the net assets. On March 31, 2016, the leverage had increased to CHF
332.5 mn, or 12.8% of the net assets. The increase was attributed to the
dividend pay-out of CHF 160 mn and the increase of BB Biotech's portfolio
exposure to smaller and mid cap biotech companies.
Asymmetrical market reactions offer opportunity for future performance
The biotech industry's continued progress is dependent on successful innovation,
demonstrated by positive late stage clinical trials and ultimately new product
approval status and successful commercialization. Unlike prior years, biotech
equity markets showed muted responses to company announcements of progress
during the first quarter of 2016. BB Biotech anticipates this sentiment to be
temporary and continues to believe that developments and launch of innovative
medicines will drive share price appreciation among our holdings.
Gilead achieved regulatory approvals for its TAF-containing HIV single tablets.
TAF is Gilead's next generation Viread (Tenofovir) maintaining Viread's strong
efficacy profile but with an improved side effect profile with TAF having less
impact on the patient's bones and kidneys. TAF is the backbone product for
Gilead to maintain leadership in the HIV market and to overcome the loss of
exclusivity for Viread in the coming years. In March, the US FDA approved
Odefsey, a fixed-dose combination containing Emtricitabine, Rilpivirine and TAF.
In Europe, the CHMP adopted a positive opinion for Descovy, a fixed-dosed
combination of Emtricitabine and TAF.
Actelion received a positive CHMP opinion for Selexipag in January 2016. Due to
procedural changes, the EMA re-confirmed its positive recommendation once again
in late March. BB Biotech now expects European launch during the second quarter
of 2016.
Novo Nordisk shares fell in value when management updated its long-term
financial goals for top line growth from mid-teens down to the 10%. The company
regained some of the lost ground following announcement of two positive results
from two important clinical studies. The LEADER study of Victoza in more than
9000 adult type 2 diabetic patients showed a reduction of cardiovascular death,
non-fatal myocardiac infarction and non-fatal stroke for Victoza in combination
with standard of care. The SWITCH study showed that Tresiba is superior to
Sanofi's Lantus for avoidance of hypoglycemia, both for symptomatic and
nocturnal events. Both SWITCH and LEADER are expected to support further growth
for Novo Nordisk's leading diabetes franchise for years to come.
Alder, a newer holding of BB Biotech focusing on CNS-related disorders, also
reported positive clinical trial data. Alder reported two positive Phase II
migraine prevention trials for ALD403, an anti-CGRP antibody. In addition to
these data, Alder announced successful outcomes for the subcutaneous formulation
of its CGRP antibody, opening the door for them to pursue development of a self-
administered medication.
Markets were on the other hand surprised by the "refuse to file" letter issued
by the FDA for PTC's Ataluren. Consequently, PTC's share price fell more than
80% in the first quarter of 2016. PTC has stated that they expect shortly a
final European regulatory decision on Ataluren, in which it currently sells in
some European countries based on a conditional approval.
In summary, large cap biotech share prices corrected by 10-20%, mid caps by
20-40% and a range of small caps fell by 40-50% during the first three months of
2016, often despite progress with their research programs. In
BB Biotech's view, the important milestones achieved have not generally been
factored into company valuations yet. The team believes that these positive
events presage upside as the biotech market recovers its poise.
Outlook
BB Biotech anticipates 2016 to remain volatile for biotechnology equities.
Nevertheless, product approvals and read-outs rate from key clinical trials are
expected to accelerate throughout the remainder of the year and offer the
potential for significant growth in share price valuations. Important regulatory
milestones anticipated for companies in BB Biotech's portfolio include:
* Intercept - obeticholic acid (OCA) for treating primary biliary cirrhosis
* Gilead - fix dose combination of Sofosbuvir/Velpatasvir for treating all
genotypes of chronic hepatitis C viral infections
* Neurocrine - Valbenazine for treating patients suffering from tardive
dyskinesia
* Radius - Abaloparatide-SC for the treatment of postmenopausal women with
osteoporosis
* Medivation - label expansion for Xtandi for prostate cancer
Many important clinical trial results are also expected to impact company share
prices, including:
* Tesaro - Niraparib, a PARP inhibitor for treating ovarian cancer patients
and
* Clovis - Rucaparib, another PARP inhibitor for treating ovarian cancer
patients
* Vertex - VX-661/ivacaftor combination for treating cystic fibrosis patients
that are heterozygous for the F508 deletion
* Incyte - Epacadostat in multiple Phase II studies in combination with
various PD1 antibodies for treating non-small cell lung cancer patients
* Celgene - Revlimid tested in the REMARC study for patients with diffuse
large B-cell lymphoma
* Novavax - RSV vaccine Phase III data for elderly persons
Many more milestones are anticipated in 2016 and these are expected to support
the strong fundamentals of the portfolio and the biotechnology sector.
With large pharmaceutical companies declaring their interest in M&A we may see
increased consolidation with opportunities for favorable exit valuations for
some biotech firms. In BB Biotech's view, such take-over activity, while
inherent unpredictable in timing and targets, is likely to impact the biotech
markets the most in the short term. The portfolio continues to focus on
innovations leading to effective and efficient treatment options.
The complete interim report as at March 31, 2016 is available on
www.bbbiotech.com
For further information:
Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel.
+41 44 267 67 00
Dr. Silvia Schanz, ssc(at)bellevue.ch
Maria-Grazia Iten-Alderuccio, mga(at)bellevue.ch
Claude Mikkelsen, cmi(at)bellevue.ch
Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel.
+41 44 267 67 00
Tanja Chicherio, tch(at)bellevue.ch
b-public AG, Pfingstweidstrasse 6, 8005 Zürich, Switzerland, tel.
+41 79 423 22 28
Thomas Egger, teg(at)b-public.ch
www.bbbiotech.com
Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and
is one of the world's largest investors in this sector. BB Biotech is listed in
Switzerland, Germany and Italy. Its investments are focused on listed companies
that are developing and commercializing novel medical treatments and cures. BB
Biotech's investment selection process is guided by the fundamental research and
analysis of physicians and molecular biologists. Its Board of Directors has many
years of experience in industry and science.
Disclaimer
This release contains forward-looking statements and expectations as well as
assessments, beliefs and assumptions. Such statements are based on the current
expectations of BB Biotech, its directors and officers, and are, therefore,
subject to risks and uncertainties that may change over time. As actual
developments may significantly differ, BB Biotech and its directors and officers
accept no responsibility in that regard. All forward-looking statements included
in this release are made only as of the date of this release and BB Biotech and
its directors and officers assume no obligation to update any forward-looking
statements as a result of new information, future events or other factors.
Composition of BB Biotech's portfolio as of March 31, 2016
(in % of securities, rounded values)
Celgene 11.9%
Actelion 10.1%
Incyte 9.1%
Ionis Pharmaceuticals 9.0%
Gilead 8.4%
Alexion Pharmaceuticals 4.7%
Radius Health 4.5%
Neurocrine Biosciences 4.1%
Medivation 3.9%
Novo Nordisk 3.9%
Vertex Pharmaceuticals 3.6%
Agios Pharmaceuticals 2.9%
Alnylam Pharmaceuticals 2.5%
Regeneron Pharmaceuticals 2.4%
Swedish Orphan Biovitrum 2.4%
Halozyme Therapeutics 2.3%
Tesaro 1.8%
Juno Therapeutics 1.6%
Novavax 1.4%
Alder Biopharmaceuticals 1.2%
Cempra 1.2%
Kite Pharma 1.1%
Intercept Pharmaceuticals 1.1%
Probiodrug 0.9%
Sage Therapeutics 0.9%
Esperion Therapeutics 0.6%
Prothena Corp. 0.5%
Infinity Pharmaceuticals 0.5%
Puma Biotechnology 0.4%
Clovis Oncology 0.3%
Achillion Pharmaceuticals 0.3%
Cidara Therapeutics 0.3%
PTC Therapeutics 0.3%
Radius Health warrants 04/23/2018 0.1%
Radius Health warrants 02/19/2019 0.1%
Merck & Co Inc Contingent Value Rights - ex Trius/Cubist 0.0%
Total securities CHF 2 930.5 mn
Other assets CHF 22.0 mn
Other payables CHF (354.5) mn
Total shareholders' equity CHF 2 597.9 mn
Treasury shares (in % of company) (1)) 6.5%
1) Corresponds to the total of all own shares held including the second trading
line
Media release:
http://hugin.info/130285/R/2005645/740866.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BB BIOTECH AG via GlobeNewswire
[HUG#2005645]
Unternehmensinformation / Kurzprofil:
Datum: 22.04.2016 - 07:00 Uhr
Sprache: Deutsch
News-ID 465781
Anzahl Zeichen: 20032
contact information:
Town:
Schaffhausen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 270 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BB BIOTECH AG: Challenging first quarter for biotech investments"
steht unter der journalistisch-redaktionellen Verantwortung von
BB BIOTECH AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
